Navigation Links
Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
Date:6/8/2009

loodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-seven patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
2. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
5. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
10. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
11. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... ( http://www.researchandmarkets.com/research/vzhr6h/video ) has announced the addition of ... Growth, Trends and Forecast 2014 - 2020" report to ... of fascination since the era of the cold war between ... Russia. Earlier even a small glimpse of human form was ...
(Date:1/23/2015)... 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW ... for operable and inoperable solid tumor cancers, announced today that ... th Annual Phacilitate Immunotherapy Forum in Washington ... will take place on January 26 at 10:30 a.m. EST ...
(Date:1/23/2015)... baseball,s all-time hits leader, is the new spokesperson for the ... has announced. "Pete,s a Hall of Famer in ... board with Myoflex," said Ducere Pharma Chief Executive Officer ... known across all generations. The passion and intensity that Pete ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 The City of West ... 10 a.m., to commemorate the 42nd anniversary of the Supreme Court ... , “It’s been 42 years since the Roe vs. Wade decision ... still as present as ever,” said City of West Hollywood Councilmember ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release ... for kids with cancer. The Chemo Duck App, available on iTunes ... enjoyable games to help children of all ages living with cancer ... keep kids entertained, educated and at ease while waiting for clinic ...
(Date:1/22/2015)... 2015 VogueQueen is a seasoned and trusted ... many designers are thrilled to have it lead the wedding ... new collection of prom dresses for the global market. , ... strategic vision and he focuses on continuing the goal of ...
(Date:1/22/2015)... 2015 Angelweddingdress is a famous wedding dress ... customers to follow it on Facebook, Twitter, and Pinterest. The ... gift. Angelweddingdress draws a lottery every week. , Moreover, the ... 28, 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... , PRINCETON, N.J., July 29 ... for its second quarter ended June 30, 2009 of $0.67 per ... the sale of its centralized ECG business in 2007. Excluding the ... , "On a consolidated basis, second quarter net revenues ...
... , ARLINGTON, Va., July 29 In ... medical equipment and services (durable medical equipment) and about the ... for Homecare has developed a "Myth vs. Reality" list to ... The American Association for Homecare urges members of the media ...
... in those with known heart disease , WEDNESDAY, July 29 ... heart arteries to a standard test of blood vessel function ... to develop serious problems, a new German study indicates. , ... could help identify those who are at highest risk for ...
... , , Says ... , WASHINGTON, July 29 In today,s Washington Post, ... health care, entitled: "Crossing Our Lines: Working Together to Reform the ... expand coverage and control costs." According to Marcus, the recently released report, ...
... , , , BOSTON, July ... teenagers, it is also extremely common in adult women. Studies show ... ages of 20-29 and more than 25 percent of women between ... are far more likely to report having acne than men. While ...
... Experts warn against politicizing their placement , , WEDNESDAY, ... AEDs, can save the life of someone who is ... they be placed for maximum benefit? , In two ... , researchers focused on answering that question. , In ...
Cached Medicine News:Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 2Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 3Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 4Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 5Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 6Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 7Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 8Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 9Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 10Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 11Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 12Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 13Health News:American Association for Homecare Sets the Record Straight About Recent Home Medical Equipment Issues in the News 2Health News:American Association for Homecare Sets the Record Straight About Recent Home Medical Equipment Issues in the News 3Health News:Calcium Scan of Arteries Helps Spot Big Trouble 2Health News:Calcium Scan of Arteries Helps Spot Big Trouble 3Health News:In Case You Missed It: The Washington Post's Ruth Marcus: A Bipartisan Plan on Health Care? Try Two 2Health News:Hormonal Therapies Offer Effective Solutions for Many Adult Women With Acne 2Health News:Hormonal Therapies Offer Effective Solutions for Many Adult Women With Acne 3Health News:Hormonal Therapies Offer Effective Solutions for Many Adult Women With Acne 4Health News:Put Defibrillators in High-Traffic Spots, Studies Urge 2
... II system is the Cambridge ... Alternans (MTWA) testing platform which ... cardiac death risk stratification. This ... as it can be configured ...
... The Volk G-1 trabeculum provides the highest ... Perfect for viewing and treating the trabecular meshwork. ... of the anterior chamber angle while the central ... view the posterior pole for signs of glaucoma ...
... Volks Disposable SSV® Vitrectomy Lenses are a family ... enable a view of a particular region of ... lens element weighs less than 1 gram and ... the typical shape of a human cornea. Lenses ...
... Prism are designed for midperipherical ... for tractional retinal detachments (PDR, ... detachment. They can be used ... midperipheral laser applications. Direct image ...
Medicine Products: